|本期目录/Table of Contents|

[1]陈　茜,刘　华,蒋佳露.阿奇霉素对MPP 患儿的疗效及对血清sIL-2R、IL-6、IL-17 及IL-23的影响[J].传染病信息,2019,02:142-144147.
　CHEN Xi*,LIU Hua,JIANG Jia-lu.Treatment efficacy of azithromycin on children with MPP and serum sIL-2R, IL-6, IL-17 and IL-23[J].Infectious Disease Information,2019,02:142-144147.
点击复制

阿奇霉素对MPP 患儿的疗效及对血清sIL-2R、IL-6、IL-17 及IL-23的影响(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年02期
页码:
142-144147
栏目:
论 著
出版日期:
2019-05-15

文章信息/Info

Title:
Treatment efficacy of azithromycin on children with MPP and serum sIL-2R, IL-6, IL-17 and IL-23
文章编号:
1007-8134(2019)02-0142-04
作者:
陈　茜; 刘　华; 蒋佳露
510700 广州，中山大学附属第一医院（东院）儿科
Author(s):
CHEN Xi*;  LIU Hua;  JIANG Jia-lu
Department of Pediatrics, The First Affiliated Hospital (East Hospital), Sun Yat-sen University, Guangzhou 510700, China
关键词:
阿奇霉素; 肺炎支原体; 血清白细胞介素-2 受体; 白细胞介素-6; 白细胞介素-17; 白细胞介素-23
Keywords:
azithromycin;  Mycoplasma pneumoniae;  serum interleukin-2 receptor;  interleukin-6;  interleukin-17;  interleukin-23
分类号:
R725.6
DOI:
10.3969/j.issn.1007-8134.2019.02.011
文献标识码:
A
摘要:
目的　探讨阿奇霉素治疗肺炎支原体肺炎（mycoplasma pneumoniae pneumonia, MPP）患儿的临床效果及对患 儿血清可溶性白细胞介素-2 受体（soluble interleukin-2 receptor, sIL-2R）、IL-6、IL-17、IL-23 水平的影响。方法　选取我 院2018 年1—8 月收治的142 例MPP 患儿作为研究对象，采用随机数字表法分为阿奇霉素组和红霉素组各71 例，2 组基础 治疗保持一致；对比2 组患儿的临床效果，sIL-2R、IL-6、IL-17 及IL-23 水平，各项临床症状缓解时间及不良反应。 结果　阿奇霉素组的咳嗽消失时间、肺部啰音消失时间、退热时间均短于红霉素组（P 均＜ 0.05）；治疗前，2 组患儿的 sIL-2R、IL-6、IL-17 及IL-23 水平差异无统计学意义（P 均＞ 0.05）；治疗7 d 后，阿奇霉素组患儿的sIL-2R、IL-6、IL-17 及IL-23 水平均低于红霉素组（P 均＜ 0.05）；治疗10 d 后，阿奇霉素组的临床效果优于红霉素组（P ＜ 0.05）；阿奇霉素 组的不良反应发生率为5.63% 低于红霉素组的16.90%（P ＜ 0.05）。结论　阿奇霉素治疗MPP 患儿效果优于红霉素，能有 效缓解患儿的临床症状并降低sIL-2R、IL-6、IL-17 及IL-23 水平。
Abstract:
Objective　To investigate the clinical effects of azithromycin in the treatment of children with mycoplasma pneumoniae pneumonia (MPP) and its influence on serum interleukin-2 receptor (sIL-2R), IL-6, IL-17, and IL-23 levels. Methods　A total of 142 MPP children who were admitted to our hospital from January 2018 to August 2018 were randomly divided into the azithromycin group and the erythromycin group, with 71 cases in each group. The basic treatment was consistent in both groups. Clinical effects, serum sIL-2R, IL-6, IL-17, IL-23 levels, various clinical symptoms relief time and adverse reactions were compared between 2 groups. Results　The disappearance time of cough, the disappearance time of lung rale and the time of fever clearance were shorter in the azithromycin group than those in the erythromycin group (P ＜ 0.05). Before treatment, the serum sIL-2R, IL-6, IL-17 and IL-23 levels of the 2 groups showed no significant difference (P ＞ 0.05). After 7 days of treatment, the serum levels of sIL-2R, IL-6, IL-17 and IL-23 were lower in the azithromycin group than those in the erythromycin group (P ＜ 0.05). After 10 days of treatment, the clinical effect of the azithromycin group was better than that of the erythromycin group (P ＜ 0.05). The incidence of adverse reactions in the azithromycin group was 5.63%, which was lower than that in the erythromycin group (16.90%) (P ＜ 0.05). Conclusions　Azithromycin is superior to erythromycin in the treatment of children with MPP, which can effectively alleviate the clinical symptoms and reduce serum sIL-2R, IL-6, IL-17, IL-23 levels.

参考文献/References


[1] Yang D, Chen L, Chen Z. The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings［J］. PLoS One, 2018, 13(1):e0191951.
[2] Yin YD, Wang R, Zhuo C, et al. Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study［J］. J Thorac Dis, 2017, 9(10):3774-3781.
[3] 陈嘉慧，印根权，余嘉璐，等. 红霉素与阿奇霉素治疗小儿 肺炎支原体肺炎的临床研究［J］. 中国临床药理学杂志， 2015，31(8):587-589.
[4] 张莉娅. 阿奇霉素治疗小儿支原体肺炎的疗效观察［J］. 中 国医院用药评价与分析，2016，26(4):456-458.
[5] 吴秋英，吴娅. 中医辨证分型与阿奇霉素联用治疗小儿肺 炎支原体肺炎的临床研究［J］. 中华中医药学刊，2016， 34(3):754-757.
[6] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和 治疗指南（2016 年版）［J］. 中华结核和呼吸杂志，2016， 39(4):253-279.
[7] 黄静，代永红. 难治性新生儿肺炎危险因素分析［J］. 现代 仪器与医疗，2016，22(3):65-66.
[8] Akashi Y, Hayashi D, Suzuki H, et al. Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae［J］. J Gen Fam Med, 2018, 19(6):191- 197.
[9] Del Valle-Mendoza J, Orellana-Peralta F, Marcelo-Rodríguez A, et al. High prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with acute respiratory infections from Lima, Peru［J］. PLoS One, 2017, 12(1):e0170787.
[10] 刘晓燕，王曼知. 阿奇霉素与红霉素对支原体肺炎患儿血清 hs-CRP、TNF-α、IL-8 的影响和治疗效果比较［J］. 湖南师 范大学学报（医学版），2017，14(3):60-63.
[11] 王培养，顾承萍. 阿奇霉素联合布地奈德治疗小儿支原体 肺炎的临床疗效分析［J］. 中国微生态学杂志，2017， 29(5):574-576.
[12] 李晓品，李艳红，许凤勤，等. 阿奇霉素对肺炎支原体肺炎 感染患儿Th1/Th2指标的影响研究［J］. 中华医院感染学杂志， 2016，26(16):3797-3799.
[13] 李晓侠，马健. 甲泼尼龙联合阿奇霉素对难治性支原体肺炎 患儿淋巴细胞亚群及血浆凝血酶调节蛋白、D- 二聚体的影响 ［J］. 中国妇幼保健，2017，32(23):5914-5917.
[14] 曾国庆，刘国英，陈瑞林，等. 阿奇霉素序贯疗法治疗小儿 肺炎支原体肺炎疗效观察［J］. 中国中西医结合儿科学， 2016，8(1):46-48.
[15] 陆丽骏，乔晓辉，李保法，等. 阿奇霉素联合转移因子口服 溶液治疗小儿支原体肺炎的疗效及对肺功能的影响研究［J］. 中华医院感染学杂志，2018，28(7):1100-1103.

备注/Memo

备注/Memo:

[ 通信作者]　陈茜，E-mail: chen_laoxi@126.com
*Corresponding author, E-mail: chen_laoxi@126.com
更新日期/Last Update: 2019-05-15